Differential influences of @entity6211 palmitoyltransferase-1 inhibition and XXXX on cardiac growth and sarcoplasmic reticulum phosphorylation.

@entity55587 @entity101 @entity6211 @entity141 @entity1378 @entity35 @entity1954
To characterize interventions resulting in 'physiological' growth of the heart, @entity35 -Kyoto (WKY) @entity35 and spontaneously @entity101 @entity35 (SHR) had @entity1378 induced (0.05 mg.kg-1.day-1 @entity1954 for 6 days) or were treated with a high dose of the @entity6211 palmitoyltransferase-1 inhibitor, @entity55587 (15 mg.kg-1.day-1 for 5 weeks). Etomoxir increased cardiac growth evenly, but @entity1378 resulted in an over-proportional higher right ventricular weight. Both interventions increased the proportion of the myosin isozyme V1. The rate of sarcoplasmic reticulum (SR) @entity141 uptake was increased to a greater extent in @entity1378 @entity35 than in etomoxir-treated @entity35 (P < 0.05). Left ventricular levels of immunoreactive phospholamban (semiquantitative ELISA) were moderately decreased (P < 0.05) in @entity1378 @entity35 but not in etomoxir-treated @entity35 . The protein kinase A-catalyzed in vitro 32P-incorporation into the SR @entity141 pump modulator phospholamban was greatly reduced (P < 0.05) in @entity1378 @entity35 , indicating an increased in vivo phosphorylation. Etomoxir did not affect phospholamban phosphorylation in WKY @entity35 . Thus, both a higher in vivo phospholamban phosphorylation state and a greater number of active @entity141 pumps contributed to an increased rate of SR @entity141 uptake in @entity1378 . The etomoxir treatment primarily increased the number of active @entity141 pumps. A scheme is proposed focusing on long-term vs short-term regulation of the SR @entity141 pump/phospholamban system in diseased states.
